| Document |
Document Title |
|
WO/2023/014931A1 |
The present disclosure provides delivery vehicle compositions comprising hydroxyethyl-capped tertiary amino lipidated cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclo...
|
|
WO/2023/015239A1 |
The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor (BCR), polynucleotides encoding the CAAR, vectors...
|
|
WO/2023/006131A1 |
The invention relates to a recombinant chimeric antigen comprising, in the polypeptide chain thereof, a polypeptide corresponding to amino acids 2 to 104 of the Zika virus capsid protein or a polypeptide with an amino acid sequence with ...
|
|
WO/2023/005859A1 |
A T cell receptor (TCR), having the characteristic of binding a AQIPEKIQK (SEQ ID NO: 34)-HLAA 1101 complex. Disclosed are a multivalent TCR complex, a nucleic acid molecule encoding the TCR, a vector containing nucleic acids, a cell exp...
|
|
WO/2023/005680A1 |
Provided are a human interleukin-2 variant and the use thereof. Specifically, provided is an IL-2 variant (or a derivative thereof) having eliminated or reduced affinity with a high-affinity receptor IL-2Rα/β/γ and retaining affinity ...
|
|
WO/2023/008515A1 |
The present invention addresses the problem of providing a fusion protein that is for use in treatment or diagnosis of cancer and that is formed between a molecule recognizing a cancer cell or the like and a streptavidin variant. Accordi...
|
|
WO/2022/016270A9 |
The present disclosure provides fusion proteins with a multifunctional biologic design for programmed target engagement. In certain embodiments, the fusion proteins described herein provide for concurrent target antigen engagement and im...
|
|
WO/2023/010038A1 |
Some embodiments of the methods and compositions provided herein include methods and/or systems for increasing an activity of a cell comprising a chimeric antigen receptor (CAR), comprising use of a first nucleic acid encoding a transcri...
|
|
WO/2023/006117A1 |
Provided herein are antibodies and antigen-binding fragment thereof targeting CLL1, and chimeric antigen receptors (e.g., monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-CLL1 antigen-binding fragment...
|
|
WO/2023/006062A1 |
Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, com...
|
|
WO/2023/005219A1 |
Provided are a chimeric antigen receptor modified by ubiquitin coupling and an immune cell. The ubiquitin is coupled to a C-terminus of the chimeric antigen receptor, and is suitable for a variety of current CAR-T cell production technol...
|
|
WO/2023/280133A9 |
A fusion protein and an application thereof, the fusion protein containing a human GLP-1 polypeptide variant and an immunoglobulin Fc region; compared to the amino acid sequence shown in SEQ ID NO: 2, the amino acid sequence of the human...
|
|
WO/2023/006082A1 |
Disclosed is an antigen targeting, anti-CD16A, and immune effector cell activating trifunctional fusion protein, comprising: a CD16A binding region that specifically binds to CD16A, a tumor-associated antigen (TAA) binding region that sp...
|
|
WO/2023/006348A1 |
The invention relates to protein building block named the Self-Assembling Kelch (SAKe) protein. The protein has a stable, symmetric design with readily accessible loops that can be varied in both sequence and length to later bind larger ...
|
|
WO/2023/004368A1 |
This disclosure relates to linker polypeptides. In some embodiments, the linker polypeptide comprises a first targeting sequence; a second targeting sequence; and a first linker between the first targeting sequence and the second targeti...
|
|
WO/2023/003464A1 |
The invention relates to the field of protein engineering and biocatalysis, in particular to methods for oxygenation of aliphatic alkenes and terpenes using bacterial enzymes. Provided is a method for oxyfunctionalization of a substrate ...
|
|
WO/2023/000170A1 |
Provided is a mouse monoclonal anti-human CD147 antibody or a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 4 and VL having the amino acid of SEQ ID NO: 5, or VH having the amino acid of SEQ ID ...
|
|
WO/2023/002952A1 |
The present invention relates to fusion proteins comprising a ligand binding domain, a protease cleavage site, and a ligand moiety. The fusion proteins of the invention comprise a ligand binding domain, a ligand moiety, and a protease cl...
|
|
WO/2023/284371A1 |
Provided in the present invention are a KHL polypeptide, and the use thereof in the preparation of a TABP-EIC cell. In addition, also provided in the present invention are a KHL polypeptide conjugate, a tumor-antigen-binding polypeptide ...
|
|
WO/2023/286694A1 |
There are said to be approximately five million people worldwide who suffer from inflammatory bowel diseases including ulcerative colitis and Crohn's disease, and the development of therapeutic agents is hoped for. In particular, the dev...
|
|
WO/2023/284380A1 |
Provided is a clinical application of cells as vectors for gene therapy. Exosomes are used as primary vectors to load RNAs required for treatment, autologous or allogeneic mature somatic cells having high clinical safety or precursor cel...
|
|
WO/2023/284053A1 |
A chimeric antigen receptor targeting mesothelin, and the use thereof. The chimeric antigen receptor comprises an extracellular region, a transmembrane region and an intracellular domain which are sequentially linked, wherein the extrace...
|
|
WO/2023/288296A1 |
Provided herein are chimeric hMPV/RSV F proteins. In some aspects, the chimeric hMPV/RSV F proteins exhibit enhanced conformational stability, enhanced thermostability, and/or increased expression. Methods are also provided for use of th...
|
|
WO/2023/284733A1 |
The present invention relates to the field of biomedicine, and provides a GITR/TGF-β dual-targeted fusion protein, a conjugate and pharmaceutical composition comprising same, and a use of the fusion protein or conjugate in the preparati...
|
|
WO/2023/284700A1 |
A novel chimeric receptor composition, a recombinant vector, a cell, and an application thereof. The novel chimeric receptor composition comprises a conventional chimeric antigen receptor (CAR), and an NKG2D chimeric receptor comprising ...
|
|
WO/2023/284684A1 |
A milk-derived polypeptide derivative and applications thereof in the preparation of a drug, a health product and a food additive for the prevention and treatment of obesity, belonging to the technical field of biomedicine. The present m...
|
|
WO/2023/286766A1 |
The present invention provides a polypeptide containing an amino acid sequence (region 1) that specifically binds to a constant site of an antibody and an amino acid sequence (region 2) that specifically binds to a nucleic acid.
|
|
WO/2023/284889A1 |
The present application relates to the field of genetic engineering, specifically to a CLD protein mutant and the use thereof. The CLD protein mutant is as shown in SEQ ID NO. 4. According to the present invention, cysteine at position 6...
|
|
WO/2023/283736A1 |
Homologous dimerization (HD) peptides are described having improved self-binding. The HD peptides may comprise an amino acid sequence having the reverse configuration compared to a corresponding naturally occurring HD peptide or comprise...
|
|
WO/2023/284471A1 |
The present invention relates to a novel polypeptide for specific recognition of a prostate cancer cell, and a derivative and the use thereof. The polypeptide is obtained by means of screening a phage-polypeptide library, can specificall...
|
|
WO/2023/286841A1 |
Provided are: a chimeric antigen receptor comprising a target antigen binding region, a transmembrane region and a signal transduction region, in which the transmembrane region contains, at the C-terminal thereof, a first polypeptide sel...
|
|
WO/2023/284822A1 |
Provided are conjugates of polypeptides comprising nanobody and FGF21 linked by a polypeptide linker. Further provided are conjugates of polypeptides comprising GLP-1, nanobody, and FGF21 linked by two polypeptide linkers respectively. P...
|
|
WO/2023/286059A1 |
Compositions and methods for treating a medical condition are provided. Accordingly, there is provided a composition comprising a polypeptide comprising a GnRH receptor binding protein and a polynucleotide coding a therapeutic agent, whe...
|
|
WO/2023/286840A1 |
An anti-EGFRviii antibody that is an antibody having a specific CDR sequence and is selected from the group consisting of the antibodies (a-1) to (a-3); a polypeptide comprising the antibody; a cell capable of expressing the polypeptide;...
|
|
WO/2023/288281A2 |
The present disclosure provides fusion proteins with novel signaling properties. Disclosed embodiments include fusion proteins that comprise an extracellular component that is capable of binding to a TGFβ polypeptide, a transmembrane co...
|
|
WO/2023/280144A1 |
Provided are a fusion protein consisting of an FGF21 protein and immunoglobulin Fc or fragments thereof, and a method for treating diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver, non-alcoholic steatohepati...
|
|
WO/2023/279212A1 |
The present application discloses neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof that are effective against several SARS-CoV-2 variants. Pharmaceutical compositions comprising the antibodies or antigen-bindi...
|
|
WO/2023/282315A1 |
Provided is a method for the secretory production of an unnatural-amino-acid-containing protein. In the present invention, coryneform bacteria that have a genetic construct for secretory expression of an unnatural-amino-acid-containing p...
|
|
WO/2023/280042A1 |
The present invention relates to an anti-CD24 antibody or an antigen-binding fragment thereof capable of binding CD24 and/or capable of exerting an anti-tumor effect by means of an antibody Fc fragment and the use thereof.
|
|
WO/2023/279771A1 |
Provided in the present invention are an anti-multiple-sclerosis recombinant protein, and a preparation method therefor. The recombinant protein of the present invention comprises Mycobacterium tuberculosis heat shock protein 65 and six ...
|
|
WO/2023/272924A1 |
Provided are a novel fully human antibody for human B7H3, a chimeric antigen receptor, and uses thereof; also provided are a novel fully human anti-human B7H3 antibody, a chimeric antigen receptor containing the antibody, and genetically...
|
|
WO/2023/274104A1 |
Provided is an intein C-terminal sequence variant, wherein compared with an amino acid sequence as shown in SEQ ID NO. 1, the intein C-terminal sequence variant contains at least one mutation positioned at amino acid positions selected f...
|
|
WO/2023/276395A1 |
To simultaneously improve therapeutic efficacy and reduce side effects in an adoptive immunotherapy, the present invention provides a novel technique for enhancing functions such as proliferation ability of immune cells to be used in the...
|
|
WO/2023/273958A1 |
Provided is a hexavalent trispecific antibody. The hexavalent trispecific antibody is a dimer formed by two monomers; each monomer comprises a heavy chain, a first light chain, and a second light chain; from N terminal to C terminal, the...
|
|
WO/2023/273914A1 |
Provided in the present invention is an antibody against human CD3 or an antigen-binding fragment thereof; also provided are a nucleic acid molecule encoding the antibody, an expression vector expressing the antibody and a host cell, as ...
|
|
WO/2023/274382A1 |
A multi-targets synthetic TCR and antigen/antibody receptor (M-STA/AR), a T cell containing the M-STA/AR, and use of the M-STA/AR and the T cell.
|
|
WO/2023/274352A1 |
A binding molecule comprising a binding domain that binds to an antigen expressed on an activated hepatic stellate cells (HSC), and a functional domain that is capable of enhancing an antibody effector function such as antibody-dependent...
|
|
WO/2023/274384A1 |
Provided is an antigen-binding polypeptide specifically binding to B7H3. The antigen-binding polypeptide contains at least one complementarity determining region (CDR) of an antibody heavy chain variable region (VH), wherein the VH conta...
|
|
WO/2022/266778A1 |
BCMA T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds BCMA, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypept...
|
|
WO/2022/267097A1 |
A polypeptide targeting integrin α6 and the use thereof. The polypeptide has a sequence motif of RWYD, and is stronger in affinity, wherein the equilibrium dissociation constant KD reaches the level of nM, and the affinity is greatly im...
|
